Skip to main content
. Author manuscript; available in PMC: 2016 Apr 14.
Published in final edited form as: Int J Stat Med Res. 2016;5(1):17–40. doi: 10.6000/1929-6029.2016.05.01.3

Table A-8.

Rheumatoid Arthritis: Correlations with Prevalent Comorbid Conditions

Rheumatoid Arthritis Comorbid Condition
RA1 RA2 RA3 CC1 CC2
Rheumatoid arthritis (N=493)
 RA1 Joint paina
 RA2 RA severity 0.53
 RA3 RA QOL impact 0.49 0.78
Obesity (N=154)
 Ob1 Body mass index 0.21 0.24 0.25
 Ob2 Obesity severity 0.31 0.33 0.31 0.58
 Ob3 Obesity QOL impact 0.23 0.36 0.37 0.45 0.72
Diabetes (N=90)
 Di2 Diabetes severity 0.00 0.11 0.07 ---
 Di3 Diabetes QOL impact 0.11 0.32 0.36 --- 0.52
Osteoarthritis (N=177)
 OA2 OA severity 0.29 0.29 0.31 ---
 OA3 OA QOL impact 0.33 0.32 0.45 --- 0.83
Allergies-chronic (N=156)
 Allc2 Allergy-chronic severity 0.31 0.28 0.24 ---
 Allc3 Allergy-chronic QOL impact 0.26 0.25 0.33 --- 0.68
Allergies-seasonal (N=220)
 Alls2 Allergy-seasonal severity 0.19 0.30 0.22 ---
 Alls3 Allergy-seasonal QOL impact 0.28 0.32 0.31 --- 0.76
Anemia (N=91)
 An2 Anemia severity 0.31 0.28 0.23 ---
 An3 Anemia QOL impact 0.27 0.14 0.09 --- 0.80
Cancer, non-skin (N=56)
 Ca2 Cancer severity 0.23 0.03 0.08 ---
 Ca3 Cancer QOL impact 0.29 −0.01 −0.11 --- 0.49
Chronic back problems (N=200)
 Bp2 Back severity 0.47* 0.55* 0.54* ---
 Bp3 Back QOL impact 0.45 0.48* 0.55* --- 0.84
Depression (N=99)
 De2 Depression severity 0.26 0.42 0.41 ---
 De3 Depression QOL impact 0.29 0.34 0.42 --- 0.87
Dermatitis/skin conditions (N=85)
 Sk2 Dermatitis severity 0.10 0.21 0.17 ---
 Sk3 Dermatitis QOL impact 0.27 0.30 0.27 --- 0.77
Erectile dysfunction (N=50)
 Ed2 Erectile dysfunction severity 0.23 0.23 0.17 ---
 Ed3 Erectile dysfunction QOL impact 0.47* 0.40 0.34 --- 0.51
Fibromyalgia (N=72)
 FM2 Fibromyalgia severity 0.49* 0.49* 0.47* ---
 FM3 Fibromyalgia QOL impact 0.49* 0.49* 0.51* --- 0.91
Hearing, trouble (N=77)
 He2 Hearing severity 0.03 0.19 0.13 ---
 He3 Hearing QOL impact 0.13 0.29 0.37 --- 0.53
Hypertension (N=269)
 Hy2 Hypertension severity 0.26 0.36 0.34 ---
 Hy3 Hypertension QOL impact 0.32 0.41 0.45 --- 0.58
Hypothyroidism (N=90)
 Th2 Hypothyroidism severity 0.36 0.28 0.32 ---
 Th3 Hypothyroidism QOL impact 0.24 0.21 0.30 --- 0.75
Irritable bowel syndrome (N=74)
 Ib2 IBS severity 0.39 0.15 0.05 ---
 Ib3 IBS QOL impact 0.45 0.22 0.22 --- 0.83
Joint problems, foot/ankle (N=167)
 Fa2 Foot/ankle severity 0.33 0.49* 0.46* ---
 Fa3 Foot/ankle QOL impact 0.31 0.44 0.49* --- 0.80
Joint problems, hip/knee (N=275)
 Hk2 Hip/knee severity 0.40 0.38 0.43 ---
 Hk3 Hip/knee QOL impact 0.42 0.41 0.55* --- 0.81
Limb, limitations in use (N=75)
 Lm2 Limb severity 0.33 0.24 0.25 ---
 Lm3 Limb QOL impact 0.25 0.25 0.43 --- 0.70
Migraine headaches (N=108)
 Mi2 Migraine severity 0.15 0.12 0.12 ---
 Mi3 Migraine QOL impact 0.29 0.20 0.19 --- 0.84
Osteoporosis (N=76)
 Os2 Osteoporosis severity 0.38 0.52* 0.46* ---
 Os3 Osteoporosis QOL impact 0.38 0.42 0.46* --- 0.72
Ulcer/stomach disease (N=76)
 Ul2 Ulcer/stomach severity 0.32 0.46* 0.44 ---
 Ul3 Ulcer/stomach QOL impact 0.27 0.42 0.48* --- 0.78
Vision, trouble (N=84)
 Vi2 Vision severity 0.12 0.20 0.26 ---
 Vi3 Vision QOL impact 0.24 0.41 0.41 --- 0.63

CC1 = Symptom measure for comorbid condition; CC2 = Severity measure for comorbid condition.

Higher scores on severity and impact items indicate greater disease severity or greater disease impact.

a

Joint pain defined in Table 1. Higher scores indicate greater joint pain.

*

Heterotrait correlations r>0.45 (absolute value) failed convergent-discriminant 1-tailed test. Median (r=0.53) correlation from convergent triangle selected for convergent-discriminant comparisons.